Anika Therapeutics Analyst Ratings
Anika Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 30.58% | Barrington Research | → $24 | Upgrades | Market Perform → Outperform |
| 08/10/2023 | 25.14% | Stephens & Co. | $28 → $23 | Maintains | Equal-Weight |
| 05/31/2023 | 52.34% | Stephens & Co. | → $28 | Reiterates | Equal-Weight → Equal-Weight |
| 04/14/2023 | 52.34% | Stephens & Co. | → $28 | Reiterates | → Equal-Weight |
| 03/07/2023 | — | Barrington Research | Downgrades | Outperform → Market Perform | |
| 11/09/2022 | 68.66% | Barrington Research | → $31 | Upgrades | Market Perform → Outperform |
| 10/14/2022 | 41.46% | Stephens & Co. | → $26 | Reinstates | → Equal-Weight |
| 03/09/2022 | — | Stephens & Co. | Downgrades | Overweight → Equal-Weight | |
| 11/16/2021 | 199.24% | Stephens & Co. | → $55 | Initiates Coverage On | → Overweight |
| 07/16/2021 | 150.27% | UBS | → $46 | Initiates Coverage On | → Neutral |
| 12/16/2020 | 133.95% | Barrington Research | → $43 | Upgrades | Market Perform → Outperform |
| 01/21/2020 | 231.88% | Sidoti & Co. | → $61 | Upgrades | Neutral → Buy |
| 11/05/2019 | 57.78% | BWS Financial | → $29 | Initiates Coverage On | → Sell |
| 09/23/2019 | — | First Analysis | Downgrades | Strong Buy → Outperform | |
| 02/22/2019 | 123.07% | Sidoti & Co. | $56 → $41 | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月14日 | 30.58% | 巴灵顿研究公司 | →$24 | 升级 | 市场表现优于→ |
| 2023年08月10日 | 25.14% | 斯蒂芬斯公司 | $28→$23 | 维护 | 等重 |
| 2023年05月31日 | 52.34% | 斯蒂芬斯公司 | →$28 | 重申 | 等重→等重 |
| 04/14/2023 | 52.34% | 斯蒂芬斯公司 | →$28 | 重申 | →等重 |
| 03/07/2023 | - | 巴灵顿研究公司 | 评级下调 | 跑赢→市场表现 | |
| 11/09/2022 | 68.66% | 巴灵顿研究公司 | →$31 | 升级 | 市场表现优于→ |
| 10/14/2022 | 41.46% | 斯蒂芬斯公司 | →$26 | 恢复 | →等重 |
| 03/09/2022 | - | 斯蒂芬斯公司 | 评级下调 | 超重→等重 | |
| 2021年11月16日 | 199.24% | 斯蒂芬斯公司 | →$55 | 开始承保 | →超重 |
| 07/16/2021 | 150.27% | 瑞银集团 | →$46 | 开始承保 | →中性 |
| 12/16/2020 | 133.95% | 巴灵顿研究公司 | →$43 | 升级 | 市场表现优于→ |
| 2020/01/21 | 231.88% | 西多蒂公司 | →$61 | 升级 | 中性→购买 |
| 2019年11月05日 | 57.78% | BWS金融 | →$29 | 开始承保 | →销售 |
| 2019年09月23日 | - | 第一次分析 | 评级下调 | 强势买入→跑赢大盘 | |
| 2019年02月22日 | 123.07% | 西多蒂公司 | $56→$41 | 评级下调 | 购买→中性 |
What is the target price for Anika Therapeutics (ANIK)?
Anika Treeutics(Anik)的目标价格是多少？
The latest price target for Anika Therapeutics (NASDAQ: ANIK) was reported by Barrington Research on August 14, 2023. The analyst firm set a price target for $24.00 expecting ANIK to rise to within 12 months (a possible 30.58% upside). 7 analyst firms have reported ratings in the last year.
巴灵顿研究公司于2023年8月14日报道了Anika治疗公司(纳斯达克：ANIK)的最新目标价。这家分析公司将目标价定为24美元，预计Anik将在12个月内上涨(可能上涨30.58%)。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Anika Therapeutics (ANIK)?
Anika Treeutics(Anik)的最新分析师评级是什么？
The latest analyst rating for Anika Therapeutics (NASDAQ: ANIK) was provided by Barrington Research, and Anika Therapeutics upgraded their outperform rating.
巴灵顿研究公司提供了对Anika治疗公司(纳斯达克代码：ANIK)的最新分析师评级，Anika治疗公司上调了其表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for Anika Therapeutics (ANIK)?
Anika Treeutics(Anik)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anika Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anika Therapeutics was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查看公共财务报表，与Anika Treeutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Anika治疗公司的上一次评级是在2023年8月14日提交的，所以你应该预计下一次评级将在2024年8月14日左右的某个时候提供。
Is the Analyst Rating Anika Therapeutics (ANIK) correct?
分析师对Anika Treeutics(Anik)的评级正确吗？
While ratings are subjective and will change, the latest Anika Therapeutics (ANIK) rating was a upgraded with a price target of $0.00 to $24.00. The current price Anika Therapeutics (ANIK) is trading at is $18.38, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Anika Treeutics(Anik)评级被上调，目标价从0.00美元到24.00美元。Anika Treateutics(Anik)目前的交易价格为18.38美元，在分析师的预测范围内。